Dynavax Technologies
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 408
- Market Cap
- $1.4B
- Introduction
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by L...
Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine
- Conditions
- Interventions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 2428
- Registration Number
- NCT00435812
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
- Conditions
- Interventions
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT00426712
- Locations
- 🇺🇸
University of Virginia Health System, Nephrology Clinical Research Center, Charlottesville, Virginia, United States
🇺🇸West Coast Clinical Trials, Costa Mesa, California, United States
🇺🇸Covance, Austin, Texas, United States
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT00403052
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Premiere Oncology, Santa Monica, California, United States
🇺🇸Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
- Conditions
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Dynavax Technologies Corporation
- Target Recruit Count
- 738
- Registration Number
- NCT00387738
- Locations
- 🇺🇸
Research Center of Indiana, Indianapolis, Indiana, United States
🇺🇸Clinical Research of The Ozarks, Rolla, Missouri, United States
🇺🇸Atlanta Allergy & Asthma Clinic, Stockbridge, Georgia, United States